FUW-tetO-hKLF4 Citations (8)
Originally described in: A drug-inducible system for direct reprogramming of human somatic cells to pluripotency.Hockemeyer D, Soldner F, Cook EG, Gao Q, Mitalipova M, Jaenisch R Cell Stem Cell. 2008 Sep 11. 3(3):346-53. PubMed Journal
Articles Citing FUW-tetO-hKLF4
| Articles |
|---|
| Facilitators and impediments of the pluripotency reprogramming factors' initial engagement with the genome. Soufi A, Donahue G, Zaret KS. Cell. 2012 Nov 21;151(5):994-1004. doi: 10.1016/j.cell.2012.09.045. Epub 2012 Nov 15. PubMed |
KLF4 N-terminal variance modulates induced reprogramming to pluripotency.
Kim SI, Oceguera-Yanez F, Hirohata R, Linker S, Okita K, Yamada Y, Yamamoto T, Yamanaka S, Woltjen K.
Stem Cell Reports. 2015 Apr 14;4(4):727-43. doi: 10.1016/j.stemcr.2015.02.004. Epub 2015 Mar 12.
PubMed
Associated Plasmids |
| Interspecies Chimerism with Mammalian Pluripotent Stem Cells. Wu J, Platero-Luengo A, Sakurai M, Sugawara A, Gil MA, Yamauchi T, Suzuki K, Bogliotti YS, Cuello C, Morales Valencia M, Okumura D, Luo J, Vilarino M, Parrilla I, Soto DA, Martinez CA, Hishida T, Sanchez-Bautista S, Martinez-Martinez ML, Wang H, Nohalez A, Aizawa E, Martinez-Redondo P, Ocampo A, Reddy P, Roca J, Maga EA, Esteban CR, Berggren WT, Nunez Delicado E, Lajara J, Guillen I, Guillen P, Campistol JM, Martinez EA, Ross PJ, Izpisua Belmonte JC. Cell. 2017 Jan 26;168(3):473-486.e15. doi: 10.1016/j.cell.2016.12.036. PubMed |
| Metabolic control of primed human pluripotent stem cell fate and function by the miR-200c-SIRT2 axis. Cha Y, Han MJ, Cha HJ, Zoldan J, Burkart A, Jung JH, Jang Y, Kim CH, Jeong HC, Kim BG, Langer R, Kahn CR, Guarente L, Kim KS. Nat Cell Biol. 2017 May;19(5):445-456. doi: 10.1038/ncb3517. Epub 2017 Apr 24. PubMed |
| miR-524-5p of the primate-specific C19MC miRNA cluster targets TP53IPN1- and EMT-associated genes to regulate cellular reprogramming. Nguyen PNN, Choo KB, Huang CJ, Sugii S, Cheong SK, Kamarul T. Stem Cell Res Ther. 2017 Sep 29;8(1):214. doi: 10.1186/s13287-017-0666-3. PubMed |
| Reversible dual inhibitor against G9a and DNMT1 improves human iPSC derivation enhancing MET and facilitating transcription factor engagement to the genome. Rodriguez-Madoz JR, San Jose-Eneriz E, Rabal O, Zapata-Linares N, Miranda E, Rodriguez S, Porciuncula A, Vilas-Zornoza A, Garate L, Segura V, Guruceaga E, Agirre X, Oyarzabal J, Prosper F. PLoS One. 2017 Dec 27;12(12):e0190275. doi: 10.1371/journal.pone.0190275. eCollection 2017. PubMed |
| Genes Involved in the Transcriptional Regulation of Pluripotency Are Expressed in Malignant Tumors of the Uterine Cervix and Can Induce Tumorigenic Capacity in a Nontumorigenic Cell Line. Ruiz G, Valencia-Gonzalez HA, Perez-Montiel D, Munoz F, Ocadiz-Delgado R, Fernandez-Retana J, Perez-Plasencia C, Resendis-Antonio O, Gariglio P, Garcia-Carranca A. Stem Cells Int. 2019 Dec 1;2019:7683817. doi: 10.1155/2019/7683817. eCollection 2019. PubMed |
| Dissecting OCT4 defines the role of nucleosome binding in pluripotency. Roberts GA, Ozkan B, Gachulincova I, O'Dwyer MR, Hall-Ponsele E, Saxena M, Robinson PJ, Soufi A. Nat Cell Biol. 2021 Aug;23(8):834-845. doi: 10.1038/s41556-021-00727-5. Epub 2021 Aug 5. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.